{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:08:05Z","timestamp":1790888885354,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":2145,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1111\/j.1524-4733.2007.00190.x","type":"journal-article","created":{"date-parts":[[2007,6,16]],"date-time":"2007-06-16T14:08:04Z","timestamp":1182002884000},"page":"367-376","source":"Crossref","is-referenced-by-count":23,"title":["Cost-Effectiveness of Switching to Exemestane after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer"],"prefix":"10.1016","volume":"10","author":[{"given":"David","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas C.A.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo L.","family":"Montoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton C.","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1524-4733.2007.00190.x_bib10","author":"Food and Drug Administration (FDA)"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib20","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomized trials","volume":"351","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib30","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials","volume":"365","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib40","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib50","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/jco.2005.23.16_suppl.511","article-title":"BIG 1-98: randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer","volume":"23","author":"Thurlimann","year":"2005","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib60","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib70","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","article-title":"Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial","volume":"366","author":"Jakesz","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib80","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib90","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","article-title":"Markov models in medical decision making: a practical guide","volume":"13","author":"Sonnenberg","year":"1993","journal-title":"Med Decis Making"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib100","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/jnci\/dji057","article-title":"Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case\u2013control study","volume":"97","author":"Swerdlow","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib110","author":"National Cancer Institute"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib120","doi-asserted-by":"crossref","first-page":"IV75","DOI":"10.1097\/00005650-200208001-00011","article-title":"Identifying cancer relapse using SEER-Medicare data","volume":"40","author":"Earle","year":"2002","journal-title":"Med Care"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib130","author":"National Center for Health Statistics"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib140","series-title":"Red Book: Pharmacy's Fundamental Reference","author":"Fleming","year":"2004"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib150","doi-asserted-by":"crossref","unstructured":"Stokes ME, Thompson D, Montoya EL, Weinstein MC, Winer EP, Earle CC. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-Medicare data. Value Health (in press).","DOI":"10.1111\/j.1524-4733.2007.00226.x"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib160","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1006\/gyno.1999.5480","article-title":"A comparison of treatment strategies for endometrial adenocarcinoma: analysis of financial impact","volume":"74","author":"Barnes","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib170","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00198-004-1694-2","article-title":"Health care utilization and expenditures in the United States: a study of osteoporosis-related fractures","volume":"16","author":"Orsini","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib180","series-title":"Cost-Effectiveness in Health and Medicine","author":"Gold","year":"1996"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib190","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/0272989X06290497","article-title":"Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores","volume":"26","author":"Hanmer","year":"2006","journal-title":"Med Decis Making"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib200","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1098-3015(10)65649-5","article-title":"Patient-rated utilities in postmenopausal early breast cancer (EBC): a cross-country comparison","volume":"7","author":"Sorensen","year":"2004","journal-title":"Value Health"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib210","first-page":"374","article-title":"Cost-effectiveness of extended adjuvant letrozole therapy after five years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer","volume":"12","author":"Delea","year":"2006","journal-title":"Am J Manag Care"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib220","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1359\/jbmr.2000.15.7.1384","article-title":"Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures","volume":"15","author":"Oleksik","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib230","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/S0029-7844(01)01624-6","article-title":"Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk","volume":"98","author":"Armstrong","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib240","series-title":"An Introduction to the Bootstrap","author":"Efron","year":"1993"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib250","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.2005.09.121","article-title":"American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status Report 2004","volume":"25","author":"Winer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib260","doi-asserted-by":"crossref","first-page":"734","DOI":"10.7326\/0003-4819-142-9-200505030-00008","article-title":"Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women","volume":"142","author":"Schouseboe","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib270","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1200\/JCO.2000.18.18.3302","article-title":"Systematic overview of cost-utility assessments in oncology","volume":"18","author":"Earle","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib280","author":"U.S. Bureau of Labor Statistics"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib290","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1200\/JCO.2004.04.158","article-title":"HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis","volume":"22","author":"Elkin","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib300","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/cncr.20347","article-title":"The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review","volume":"101","author":"Deitcher","year":"2004","journal-title":"Cancer"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib310","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.2005.09.121","article-title":"American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004","volume":"23","author":"Winer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib320","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/annonc\/mdj048","article-title":"Comparing cost\/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2\u20133 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer","volume":"17","author":"L\u00f8nning","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib330","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/cncr.20492","article-title":"Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer","volume":"101","author":"Hillner","year":"2004","journal-title":"Cancer"},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib340","unstructured":"Locker GY. ATAC Trialists' Group. Cost-utility analysis of anastrozole versus tamoxifen as primary adjuvant therapy in postmenopausal women with early breast cancer, from a US healthcare system perspective: the 5-year completed treatment analysis of the ATAC (\u2018Arimidex', Tamoxifen alone or in Combination) trial. San Antonio Breast Cancer Symposium 2004 (abstract)."},{"key":"10.1111\/j.1524-4733.2007.00190.x_bib350","doi-asserted-by":"crossref","first-page":"5178","DOI":"10.1200\/JCO.2005.02.964","article-title":"Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis","volume":"23","author":"Punglia","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301510604743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301510604743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T03:29:23Z","timestamp":1556508563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301510604743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S1098301510604743"],"URL":"https:\/\/doi.org\/10.1111\/j.1524-4733.2007.00190.x","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}